These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 26406267

  • 1. Theory and strategy for Pneumococcal vaccines in the elderly.
    Namkoong H, Ishii M, Funatsu Y, Kimizuka Y, Yagi K, Asami T, Asakura T, Suzuki S, Kamo T, Fujiwara H, Tasaka S, Betsuyaku T, Hasegawa N.
    Hum Vaccin Immunother; 2016; 12(2):336-43. PubMed ID: 26406267
    [Abstract] [Full Text] [Related]

  • 2. The Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA): what is the future of pneumococcal conjugate vaccination in elderly?
    van Werkhoven CH, Bonten MJ.
    Future Microbiol; 2015; 10(9):1405-13. PubMed ID: 26347153
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults.
    Isturiz R, Webber C.
    Hum Vaccin Immunother; 2015; 11(7):1825-7. PubMed ID: 26076136
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.
    Vaccine; 2013 Aug 02; 31(35):3577-84. PubMed ID: 23688526
    [Abstract] [Full Text] [Related]

  • 7. Herd effects of child vaccination with pneumococcal conjugate vaccine against pneumococcal non-invasive community-acquired pneumonia: What is the evidence?
    van Werkhoven CH.
    Hum Vaccin Immunother; 2017 May 04; 13(5):1177-1181. PubMed ID: 27937061
    [Abstract] [Full Text] [Related]

  • 8. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
    Durando P, Faust SN, Fletcher M, Krizova P, Torres A, Welte T.
    Clin Microbiol Infect; 2013 Oct 04; 19 Suppl 1():1-9. PubMed ID: 24083785
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA, Gurtman A, Rice K, Pauksens K, Greenberg RN, Jones TR, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.
    Vaccine; 2013 Aug 02; 31(35):3585-93. PubMed ID: 23688527
    [Abstract] [Full Text] [Related]

  • 11. Pneumococcal conjugate vaccine use in adults - Addressing an unmet medical need for non-bacteremic pneumococcal pneumonia.
    Sings HL.
    Vaccine; 2017 Sep 25; 35(40):5406-5417. PubMed ID: 28602602
    [Abstract] [Full Text] [Related]

  • 12. Pneumococcal disease prevention among adults: Strategies for the use of pneumococcal vaccines.
    Pilishvili T, Bennett NM.
    Vaccine; 2015 Nov 27; 33 Suppl 4():D60-5. PubMed ID: 26116257
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults <50 years of age.
    Isturiz RE, Hall-Murray C, McLaughlin JM, Snow V, Schmoele-Thoma B, Webber C, Thompson A, Scott DA.
    Expert Rev Vaccines; 2018 Jan 27; 17(1):45-55. PubMed ID: 29183235
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea.
    Choi MJ, Kang SO, Oh JJ, Park SB, Kim MJ, Cheong HJ.
    Hum Vaccin Immunother; 2018 Jan 27; 14(8):1914-1922. PubMed ID: 29953307
    [Abstract] [Full Text] [Related]

  • 16. Why the recent ACIP recommendations regarding conjugate pneumococcal vaccine in adults may be irrelevant.
    Musher DM, Rodriguez-Barradas MB.
    Hum Vaccin Immunother; 2016 Jan 27; 12(2):331-5. PubMed ID: 26606172
    [Abstract] [Full Text] [Related]

  • 17. The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on serotype 19A invasive pneumococcal disease.
    Principi N, Esposito S.
    Expert Rev Vaccines; 2015 Jan 27; 14(10):1359-66. PubMed ID: 26289973
    [Abstract] [Full Text] [Related]

  • 18. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia.
    Sherwin RL, Gray S, Alexander R, McGovern PC, Graepel J, Pride MW, Purdy J, Paradiso P, File TM.
    J Infect Dis; 2013 Dec 01; 208(11):1813-20. PubMed ID: 24092845
    [Abstract] [Full Text] [Related]

  • 19. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial.
    Solanki BB, Juergens C, Chopada MB, Supe P, Sundaraiyer V, Le Dren-Narayanin N, Cutler MW, Gruber WC, Scott DA, Schmoele-Thoma B.
    Hum Vaccin Immunother; 2017 Sep 02; 13(9):2065-2071. PubMed ID: 28881165
    [Abstract] [Full Text] [Related]

  • 20. Pneumococcal Conjugated Vaccine Reduces the High Mortality for Community-Acquired Pneumonia in the Elderly: an Italian Regional Experience.
    Baldo V, Cocchio S, Gallo T, Furlan P, Romor P, Bertoncello C, Buja A, Baldovin T.
    PLoS One; 2016 Sep 02; 11(11):e0166637. PubMed ID: 27846277
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.